JP2020505034A - 細胞表面コンジュゲートならびに関連する細胞組成物および方法 - Google Patents

細胞表面コンジュゲートならびに関連する細胞組成物および方法 Download PDF

Info

Publication number
JP2020505034A
JP2020505034A JP2019539186A JP2019539186A JP2020505034A JP 2020505034 A JP2020505034 A JP 2020505034A JP 2019539186 A JP2019539186 A JP 2019539186A JP 2019539186 A JP2019539186 A JP 2019539186A JP 2020505034 A JP2020505034 A JP 2020505034A
Authority
JP
Japan
Prior art keywords
cell surface
molecule
binding
cell
streptavidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019539186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505034A5 (https=
Inventor
ローター ゲルメロート
ローター ゲルメロート
クリスティアン シュテムベルガー
クリスティアン シュテムベルガー
Original Assignee
ジュノ セラピューティクス ゲーエムベーハー
ジュノ セラピューティクス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジュノ セラピューティクス ゲーエムベーハー, ジュノ セラピューティクス ゲーエムベーハー filed Critical ジュノ セラピューティクス ゲーエムベーハー
Publication of JP2020505034A publication Critical patent/JP2020505034A/ja
Publication of JP2020505034A5 publication Critical patent/JP2020505034A5/ja
Priority to JP2022207775A priority Critical patent/JP2023052073A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
JP2019539186A 2017-01-20 2018-01-19 細胞表面コンジュゲートならびに関連する細胞組成物および方法 Pending JP2020505034A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022207775A JP2023052073A (ja) 2017-01-20 2022-12-26 細胞表面コンジュゲートならびに関連する細胞組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448936P 2017-01-20 2017-01-20
US62/448,936 2017-01-20
PCT/IB2018/000380 WO2018134691A2 (en) 2017-01-20 2018-01-19 Cell surface conjugates and related cell compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022207775A Division JP2023052073A (ja) 2017-01-20 2022-12-26 細胞表面コンジュゲートならびに関連する細胞組成物および方法

Publications (2)

Publication Number Publication Date
JP2020505034A true JP2020505034A (ja) 2020-02-20
JP2020505034A5 JP2020505034A5 (https=) 2021-03-04

Family

ID=62555094

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019539186A Pending JP2020505034A (ja) 2017-01-20 2018-01-19 細胞表面コンジュゲートならびに関連する細胞組成物および方法
JP2022207775A Withdrawn JP2023052073A (ja) 2017-01-20 2022-12-26 細胞表面コンジュゲートならびに関連する細胞組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022207775A Withdrawn JP2023052073A (ja) 2017-01-20 2022-12-26 細胞表面コンジュゲートならびに関連する細胞組成物および方法

Country Status (9)

Country Link
US (2) US11517627B2 (https=)
EP (1) EP3571221A2 (https=)
JP (2) JP2020505034A (https=)
CN (1) CN110418802A (https=)
AU (2) AU2018209400B2 (https=)
CA (1) CA3050085A1 (https=)
MA (1) MA47325A (https=)
MX (2) MX2019008538A (https=)
WO (1) WO2018134691A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020535796A (ja) * 2017-09-06 2020-12-10 フレッド ハッチンソン キャンサー リサーチ センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
US20210246189A1 (en) * 2018-09-03 2021-08-12 Technische Universitaet Muenchen A double peptide tag combining reversibility and flexible functionalization
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
CN113881701B (zh) * 2021-09-08 2024-04-19 山东大学 一种阳性转染细胞亲和分选方法及试剂盒
EP4735584A1 (en) * 2023-06-30 2026-05-06 The Children's Hospital of Philadelphia Click chemistry assisted cell surface engineering for restoring lentivirus entry

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157399A1 (en) * 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3115066A1 (en) * 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
EP0198015B2 (en) 1984-10-02 1995-07-19 Biogen, Inc. Production of streptavidin-like polypeptides
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
AU708375B2 (en) 1995-02-09 1999-08-05 University Of Washington Modified-affinity streptavidin
US6022951A (en) 1995-04-11 2000-02-08 Univ Boston Streptavidin mutants
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
EP0977770A4 (en) 1997-03-14 2000-04-05 Univ Boston DIFFERENTLY FLAVORED STREPTAVIDINE
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
RU2149023C1 (ru) 1998-04-20 2000-05-20 Ерхов Валентин Сергеевич Способ получения специфической антисыворотки к универсальному опухолевому антигену и способ диагностики злокачественных опухолей с использованием этой антисыворотки
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1520588B1 (en) 1998-07-13 2014-12-24 Board Of Regents, The University Of Texas System Uses of antibodies to aminophospholipids for cancer treatment
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
EP1178317B1 (en) 2000-07-24 2004-11-10 Health Research, Inc. Method for detection of prostate specific membrane antigen in serum
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
US20020147312A1 (en) 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
EP1390069A1 (en) 2001-05-30 2004-02-25 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
ATE408712T1 (de) 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2005070456A2 (en) 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
EP1841467A4 (en) 2005-01-14 2009-01-28 Cytogen Corp COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
WO2006078892A2 (en) 2005-01-21 2006-07-27 The Regents Of The University Of California Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy
WO2006110745A2 (en) 2005-04-08 2006-10-19 Cytogen Corporation Conjugated anti-psma antibodies
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
WO2007002905A1 (en) 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
WO2007059190A2 (en) 2005-11-14 2007-05-24 Psma Development Company, Llc. Compositions of and methods of using stabilized psma dimers
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US8229090B2 (en) 2007-04-17 2012-07-24 Verizon Patent And Licensing Inc. Voice portal communications
AU2015203742B2 (en) 2007-06-26 2016-12-01 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
US8426565B2 (en) * 2007-08-30 2013-04-23 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010135431A2 (en) 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
EP2433322A4 (en) 2009-05-19 2015-11-04 East Penn Mfg Co COMPOSITE CURRENT COLLECTOR AND RELATED METHODS
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US9023604B2 (en) 2011-07-18 2015-05-05 Iba Gmbh Method of reversibly staining a target cell
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
US20130225541A1 (en) 2012-02-24 2013-08-29 Cornell University Elevated PSMA Identifies Lethal Prostate Cancers
WO2013130177A1 (en) 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
WO2014008155A1 (en) 2012-07-02 2014-01-09 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
US20140099257A1 (en) 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
CN105073770B (zh) 2012-11-16 2019-08-06 Iba股份有限公司 链霉亲和素突变蛋白及其使用方法
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN103333249A (zh) 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP2871189A1 (en) 2013-11-07 2015-05-13 Institut Pasteur High-affinity monoclonal anti-strep-tag antibody
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
RU2680404C2 (ru) 2014-01-10 2019-02-21 Синтон Байофармасьютикалс Б. В. Способ очистки cys-связанных конъюгатов антитело-лекарственное средство
US11124845B2 (en) 2014-03-18 2021-09-21 The Johns Hopkins University PSMA-based molecular-genetic reporter system
CN113604491A (zh) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
SG11201609372UA (en) 2014-05-22 2016-12-29 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
KR102485788B1 (ko) 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
MA41046A (fr) 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
US20180022819A1 (en) 2015-02-11 2018-01-25 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
AR104484A1 (es) 2015-03-10 2017-07-26 Sorrento Therapeutics Inc Anticuerpos anti-psma como agentes terapéuticos
WO2016192613A1 (zh) 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
AU2016334623A1 (en) 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
ES2971550T3 (es) 2016-09-02 2024-06-05 Univ Cornell Receptor de antígeno quimérico de dominio I específico para ICAM-1
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157399A1 (en) * 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3115066A1 (en) * 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
**** MATERIAL SAFETY DATA SHEET **** MSDS NAME:HUMAN HER2 / ERBB2 PROTEIN, STREP TAG, JPN6021050075, 2016, pages 1 - 3, ISSN: 0004663765 *
HUMAN HER2 /ERBB2 /CD340 PROTEIN, WITH C-TWIN STREP TAG-ACROBIOSYSTEMS, JPN6021050077, 28 February 2017 (2017-02-28), ISSN: 0004663767 *
PROTEIN SCIENCE, vol. 11, JPN6021050078, 2002, pages 883 - 893, ISSN: 0005002594 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020535796A (ja) * 2017-09-06 2020-12-10 フレッド ハッチンソン キャンサー リサーチ センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
JP7407701B2 (ja) 2017-09-06 2024-01-04 フレッド ハッチンソン キャンサー センター ｓｔｒｅｐタグ特異的キメラ受容体およびその使用

Also Published As

Publication number Publication date
WO2018134691A2 (en) 2018-07-26
MX2019008538A (es) 2019-11-05
WO2018134691A8 (en) 2019-03-14
US11517627B2 (en) 2022-12-06
EP3571221A2 (en) 2019-11-27
CA3050085A1 (en) 2018-07-26
CN110418802A (zh) 2019-11-05
AU2018209400B2 (en) 2022-06-02
MA47325A (fr) 2019-11-27
MX2022015399A (es) 2023-01-16
US20200316218A1 (en) 2020-10-08
AU2018209400A1 (en) 2019-08-01
WO2018134691A3 (en) 2018-11-22
JP2023052073A (ja) 2023-04-11
US20230190952A1 (en) 2023-06-22
AU2022218531A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US20230190952A1 (en) Cell surface conjugates and related cell compositions and methods
US20250161450A1 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
AU2016363025B2 (en) Modified chimeric receptors and related compositions and methods
EP3664835B1 (en) Methods and compositions for preparing genetically engineered cells
JP2023120386A (ja) Ｔ細胞療法とｂｔｋ阻害剤との併用療法
CN107206025A (zh) 用于过继细胞治疗的方法和组合物
JP2020532954A (ja) 遺伝子操作された細胞の組成物および関連組成物を産生するための方法
US20250283037A1 (en) Methods for stimulating and transducing t cells
EP4051402B1 (en) Cell selection and/or stimulation devices and methods of use
WO2023213969A1 (en) Viral-binding protein and related reagents, articles, and methods of use
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток
HK40096189A (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
HK40096189B (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
HK1261191B (en) Modified chimeric receptors and related compositions and methods
HK1261191A1 (en) Modified chimeric receptors and related compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221226

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230106

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230111

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230303

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230308